REVENUE MEMORANDUM CIRCULAR NO. 125-2022 issued on September 6, 2022 publishes the August 17, 2022 letter from Food and Drug Administration (FDA) Director General Samuel A. Zacate, endorsing updates to the “List of VAT-Exempt Medicines” under Republic Act No. 11534 (CREATE Act), which deletes certain medicines prescribed for COVID-19 treatment.
               As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall take effect on the date of publication by the FDA of updates to the said list.